調査・レポート
2026年9月5日•1分で読めます
Parkinson’s Disease: Pathology, Symptoms, and Current Treatment Options
Parkinson’s disease is a neurodegenerative disorder marked by dopamine neuron loss and Lewy bodies, causing motor and non‑motor symptoms; treatment includes dopamine therapy and deep brain stimulation.
1
調査・レポート
2026年9月5日•1分で読めます
Parkinson’s disease: dopamine therapy limits and emerging non‑motor symptom concerns
Levodopa remains effective for motor symptoms of Parkinson’s disease, but long‑term use brings motor fluctuations and a range of non‑motor issues that heavily impact patients.
調査・レポート
2026年9月4日•1分で読めます
Study Links Long-Term Soccer Play to Brain Atrophy and Mood Issues
Preliminary research presented at the AAIC suggests former professional soccer players show greater brain atrophy and higher rates of depression and anxiety than the general population.
調査・レポート
2026年9月4日•1分で読めます
Dong-A ST Presents Nonclinical Data on GPX4 Activator DA-7505 and Tau Inhibitor DA-7503 at AAIC
Dong-A ST disclosed nonclinical results for its Alzheimer’s drug candidates targeting ferroptosis (DA-7505) and tau aggregation (DA-7503) at the AAIC in London.
調査・レポート
2026年8月31日•1分で読めます
NCIA Highlights Autophagy‑Based Brain Health Strategy and Launches NeuroAP Supplement
NCIA presented autophagy‑focused brain health research and unveiled the pharmacy‑only supplement NeuroAP at a Daegu pharmacist fair, with KAIST professor Park Ok‑nam discussing autophagy’s role in neurodegeneration.